$-0.04
(Market cap
$4 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
0.4
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-6.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-14.3
-
Face value
--
-
Shares outstanding
2,425,078
10 Years Aggregate
CFO
$-343.27 Mln
EBITDA
$-355.11 Mln
Net Profit
$-454.07 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
| -92.4 | -69.3 | -84.8 | -95.5 | -81.5 | -78.4 | -53.8 |
|
BSE Sensex*
| -9.0 | 0.3 | 1.6 | -4.6 | 5.9 | 6.5 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
| -67.7 | -75.7 | 15.9 | -88.4 | -41.9 | 381.8 | 146.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
|
1.5 | 3.8 | 4.3 | -21.2 | -508.4 | -416.5 | 0.4 | 0.8 |
| 88.6 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 249.4 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 77.9 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.3 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 106.9 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 543.7 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 611.6 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 367.9 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 149.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Curis (CRIS)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase... inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Read more
-
President, CEO, Secretary, Treasurer & Director
Mr. James E. Dentzer
-
President, CEO, Secretary, Treasurer & Director
Mr. James E. Dentzer
-
Headquarters
Lexington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Curis (CRIS)
What is the current share price of Curis Inc (CRIS) Today?
The share price of Curis Inc (CRIS) is $1.50 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Curis Inc (CRIS) has given a return of -81.48% in the last 3 years.
What is the current PB & PE ratio of Curis Inc (CRIS)?
The P/E ratio of Curis Inc (CRIS) is 0.43 times as on 21-Aug-2026.
The P/B ratio of Curis Inc (CRIS) is 0.81 times as on 21-Aug-2026, a 85 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.10 |
0.14 |
2024 |
-0.03 |
-0.20 |
2023 |
-0.08 |
0.19 |
2022 |
-0.04 |
0.06 |
2021 |
-0.02 |
0.01 |
What is the 52 Week High and Low of Curis Inc (CRIS)?
The 52-week high and low of Curis Inc (CRIS) are Rs 38.60 and Rs 1.40 as of 28-Aug-2026.
What is the market cap of Curis Inc (CRIS)?
Curis Inc (CRIS) has a market capitalisation of $ 4 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Curis Inc (CRIS)?
Before investing in Curis Inc (CRIS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.